Peter Messiaen

1.4k total citations
39 papers, 631 citations indexed

About

Peter Messiaen is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Peter Messiaen has authored 39 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 15 papers in Epidemiology and 11 papers in Virology. Recurrent topics in Peter Messiaen's work include HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (9 papers). Peter Messiaen is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (9 papers). Peter Messiaen collaborates with scholars based in Belgium, Netherlands and United States. Peter Messiaen's co-authors include Jeroen C.H. van der Hilst, Linos Vandekerckhove, Steven Vanderschueren, Bernard Lauwerys, Michel Moutschen, Inge C. Gyssens, Axel Fun, Annemarie M. J. Wensing, Monique Nijhuis and Nele Brusselaers and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Clinical Microbiology.

In The Last Decade

Peter Messiaen

36 papers receiving 624 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Messiaen Belgium	13	381	188	133	123	66	39	631
Jorge Villacian Singapore	14	495 1.3×	286 1.5×	210 1.6×	86 0.7×	112 1.7×	21	800
Lewis McCurdy United States	16	456 1.2×	324 1.7×	465 3.5×	166 1.3×	102 1.5×	38	1.0k
Sanne Jespersen Denmark	18	620 1.6×	308 1.6×	388 2.9×	58 0.5×	114 1.7×	70	981
Mahomed‐Yunus S. Moosa South Africa	17	735 1.9×	260 1.4×	434 3.3×	67 0.5×	46 0.7×	64	1.0k
Sigal Yawetz United States	14	340 0.9×	130 0.7×	234 1.8×	46 0.4×	41 0.6×	26	656
Serena Vita Italy	15	211 0.6×	133 0.7×	333 2.5×	46 0.4×	157 2.4×	49	670
Dan Ouchi Spain	15	425 1.1×	342 1.8×	149 1.1×	78 0.6×	156 2.4×	50	781
Christopher F. Rowley United States	16	414 1.1×	337 1.8×	269 2.0×	90 0.7×	59 0.9×	36	741
Kimon C. Zachary United States	14	338 0.9×	127 0.7×	233 1.8×	73 0.6×	12 0.2×	32	599
Stéphanie Haïm‐Boukobza France	16	464 1.2×	153 0.8×	276 2.1×	31 0.3×	20 0.3×	25	929

Countries citing papers authored by Peter Messiaen

Since Specialization

Citations

This map shows the geographic impact of Peter Messiaen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Messiaen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Messiaen more than expected).

Fields of papers citing papers by Peter Messiaen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Messiaen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Messiaen. The network helps show where Peter Messiaen may publish in the future.

Co-authorship network of co-authors of Peter Messiaen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Messiaen. A scholar is included among the top collaborators of Peter Messiaen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Messiaen. Peter Messiaen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beckhoven, Dominique Van, Rémy Demeester, Jens Van Praet, et al.. (2025). Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022. HIV Medicine. 26(7). 1034–1045.

Praet, Jens Van, Ben Serrien, Gilles Darcis, et al.. (2023). Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015–2021. JAIDS Journal of Acquired Immune Deficiency Syndromes. 93(2). e4–e5.

Karver, Tahilin Sanchez, Alessandro Berni, Antonella Castagna, et al.. (2023). Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial. AIDS Patient Care and STDs. 37(1). 53–59. 5 indexed citations

Florence, Éric, Jean Cyr Yombi, Sophie Henrard, et al.. (2023). Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium. HIV Medicine. 24(8). 914–924. 14 indexed citations

D’Onofrio, Valentino, Reinoud Cartuyvels, Peter Messiaen, Ivan Barišić, & Inge C. Gyssens. (2023). Virulence Factor Genes in Invasive Escherichia coli Are Associated with Clinical Outcomes and Disease Severity in Patients with Sepsis: A Prospective Observational Cohort Study. Microorganisms. 11(7). 1827–1827. 7 indexed citations

D’Onofrio, Valentino, Inge Grondman, Johan Vanwalleghem, et al.. (2022). A prospective observational cohort study to identify inflammatory biomarkers for the diagnosis and prognosis of patients with sepsis. Journal of Intensive Care. 10(1). 13–13. 8 indexed citations

Vermeersch, Sebastian, Rémy Demeester, Steven Callens, et al.. (2022). A public health value-based healthcare paradigm for HIV. BMC Health Services Research. 22(1). 13–13. 6 indexed citations

Messiaen, Peter, et al.. (2022). Acute abdominal pain: a challenging diagnosis. Acta Gastro Enterologica Belgica. 85(4). 646–647. 2 indexed citations

Florence, Éric, Michel Moutschen, Jean Cyr Yombi, et al.. (2021). Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium: A multicenter, retrospective cohort. Journal of Medical Virology. 93(5). 2971–2978. 8 indexed citations

10.

Bruyndonckx, Robin, Jeroen C.H. van der Hilst, Janneke Cox, et al.. (2020). Correction to: Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. BMC Infectious Diseases. 20(1). 5 indexed citations

11.

Bruyndonckx, Robin, Jeroen C.H. van der Hilst, Janneke Cox, et al.. (2020). Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. BMC Infectious Diseases. 20(1). 897–897. 48 indexed citations

12.

D’Onofrio, Valentino, et al.. (2020). Differentiating influenza from COVID-19 in patients presenting with suspected sepsis. European Journal of Clinical Microbiology & Infectious Diseases. 40(5). 987–995. 11 indexed citations

13.

Stessel, Björn, Liesbeth Bruckers, Ina Callebaut, et al.. (2020). Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thrombosis Research. 194. 209–215. 25 indexed citations

14.

Gyssens, Inge C., et al.. (2017). Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study.. The Netherlands Journal of Medicine. 75(6). 235–240. 23 indexed citations

15.

Hilst, Jeroen C.H. van der, Michel Moutschen, Peter Messiaen, Bernard Lauwerys, & Steven Vanderschueren. (2016). Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 10. 75–75. 73 indexed citations

16.

Messiaen, Peter, et al.. (2016). The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus‐negative immunocompromised patients: A systematic review. Transplant Infectious Disease. 19(2). 35 indexed citations

17.

Kiselinova, Maja, Anna María Geretti, Eva Malatinková, et al.. (2015). HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. Journal of Antimicrobial Chemotherapy. 70(12). dkv250–dkv250. 18 indexed citations

18.

Kiselinova, Maja, Eva Malatinková, Apostolos Beloukas, et al.. (2014). The impact of nevirapine‐ versus protease inhibitor‐based regimens on virological markers of HIV‐1 persistence during seemingly suppressive ART. Journal of the International AIDS Society. 17(4S3). 19823–19823. 3 indexed citations

19.

Messiaen, Peter, Annemarie M. J. Wensing, Axel Fun, et al.. (2013). Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. PLoS ONE. 8(1). e52562–e52562. 82 indexed citations

20.

Messiaen, Peter, Ward De Spiegelaere, José Alcamı́, et al.. (2012). Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. PLoS ONE. 7(11). e50204–e50204. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact